Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset

Heuron gets FDA green light for stroke triage and notification solution

This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea

Taro shareholders approve merger with Sun Pharma

The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world

Indica Labs receives FDA clearance for HALO AP Dx digital pathology platform

For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner

Merck to acquire life science company Mirus Bio for US$ 600 million

Acquisition will advance Merck’s integrated offering for viral vector manufacturing

Asymchem acquires former Pfizer small molecule API pilot plant in Sandwich, UK

Establishing Asymchem’s first manufacturing footprint in Europe

Cipla receives final approval for the generic version of Somatuline Depot Injection

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models